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Background: Renal cell carcinoma (RCC) is known for its ability to metastasize synchronously or metachronously to
various anatomic sites. Distinguishing histologic subtypes of metastatic RCC has become increasingly important, as
prognosis and therapy can differ dramatically between subtypes. We propose a combination of
immunohistochemistry (IHC) and molecular cytogenetics for subtyping metastatic RCC in light of these potential
therapeutic implications.
Results: Specimens from 103 cases of metastatic RCC were retrieved, including 32 cases originally diagnosed as
metastatic clear cell renal cell carcinoma (CCRCC), 8 as metastatic papillary renal cell carcinoma (PRCC), and 63
metastatic RCC without a specific subtype. Immunohistochemistry was performed with antibodies against
cytokeratin 7 (CK7) and alpha-methylacyl-CoA racemase (AMACR). Dual color interphase fluorescence in situ
hybridization was utilized to assess for deletion of chromosome 3p and trisomy of chromosomes 7 and 17 in all tu-
mors. Chromosome 3p deletion was detected in 41% of all metastatic RCC specimens, and trisomy of chromosomes
7 and/or 17 was detected in 16%. Of metastatic CCRCC, chromosome 3p deletion was detected in 63%. Of meta-
static PRCC, 75% showed trisomy of chromosomes 7 and/or 17. Of the tumors not previously classified, 6% were
positive for CK7, and 64% were positive for AMACR; 35% showed chromosome 3p deletion, and 16% showed tri-
somy of chromosomes 7 and/or 17. Combined analysis of immunohistochemistry and cytogenetics enabled reclassi-
fication of 52% of these metastatic tumors not previously classified.
Conclusion: Our findings support the utility of immunohistochemistry and cytogenetics for subtyping metastatic
RCC.
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hybridizationIntroduction
Renal cell carcinoma (RCC) comprises a heterogeneous
group of epithelial neoplasms with diverse biologic be-
haviors and variable clinical outcomes. RCC is the most
lethal of the urologic malignancies. Between 20% and
30% of patients with RCC have metastatic disease at the
time of diagnosis, and another 30% subsequently develop
metastasis after resection [1-3]. The majority of tumors* Correspondence: dx2008cn@163.com; liang_cheng@yahoo.com
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acteristically harboring abnormalities of the von Hippel-
Lindau (VHL) gene, located at chromosome 3p25 [3-9].
Defects in VHL expression result in constitutive activa-
tion of the hypoxia-inducible factor (HIF) pathway and
overexpression of vascular endothelial growth factor
(VEGF), platelet-derived growth factor (PDGF), and
other products. Inactivation of the VHL gene also en-
hances tumor cell growth though the mammalian target
of rapamycin (mTOR) pathway [8,10-12]. In contrast,
papillary renal cell carcinoma (PRCC) is the most com-
mon non-clear cell subtype of RCC, accounting for 10%-
15% of tumors. PRCC is associated with activation of the
MET pathway in a subset of tumors, resulting in atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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growth, angiogenesis, migration and invasion [6,13,14].
Knowledge of these gene pathways has enabled novel
approaches to the management of metastatic RCC [15-
17]. Currently, clinical trials with targeted therapeutic
strategies for both metastatic CCRCC and PRCC have
been intensively planned and carried out [6,13,18-26].
Although recent advances have improved patient out-
comes [20,27-29], these targeted agents are not without
toxic effects [30,31]. Optimizing the clinical outcome
and knowing when to persist with these therapies high-
light the need for accurate RCC subtyping.
Histopathologic examination of a completely resected
primary tumor is often sufficient for tumor subtyping, as
a component with prototypical morphologic features can
usually be readily appreciated. However, in the meta-
static setting, it is often challenging to discriminate be-
tween subtypes of RCC based on morphology alone,
particularly since metastatic foci are often sampled only
by core needle biopsy and are often preferentially com-
posed of high-grade tumor. Immunohistochemical ana-
lysis is valuable to identify the histogenetic origin of
metastatic malignancy [32]. Nevertheless, its use for dis-
criminating different histologic subtypes is limited and
rarely applied in prospective treatment outcome studies.
A cytogenetic hallmark of CCRCC is loss of chromo-
some 3p, which distinguishes it from other RCC sub-
types [7,8,33]. PRCC frequently exhibits chromosomal
polysomies, of which trisomy of chromosomes 7 and/or
17 are the most consistent and characteristic [7,8,34].
Because CCRCC and PRCC show different immunophe-
notypes and different characteristic cytogenetic abnor-
malities, we sought to combine these two ancillary tests
in an effort to reduce ambiguity in subtyping of metastatic
RCC. Immunophenotypes of 103 cases of metastatic RCC
were analyzed in conjunction with cytogenetic characteris-
tics as determined by fluorescence in situ hybridiza-
tion (FISH), in order to improve classification of these
neoplasms.Patients and methods
Patients
One hundred three cases of metastatic RCC diagnosed
between 2007 and 2013 were retrieved from the archives
of the Department of Pathology of the Indiana Univer-
sity School of Medicine. The histologic type was estab-
lished, when possible, according to the 2004 WHO
classification [3]. The hematoxylin and eosin slides of
these cases were reviewed, and appropriate tumor blocks
from metastatic sites were selected for immunohisto-
chemical and cytogenetic studies. This research was ap-
proved by the Indiana University Institutional Review
Board.Immunohistochemical staining
Immunohistochemistry was performed with the following
antibodies: cytokeratin 7 (CK7; monoclonal mouse anti-
human CK7 antibody, OV-TL 12/30, prediluted; Dako
Corp.) and alpha-methylacyl-CoA-racemase (AMACR/
P504S, polyclonal rabbit anti-human antibody, 13H4
clone, prediluted; Dako Corp.). Diaminobenzidine (3,
3-diaminobenzidine) was used as the chromogen. Im-
munostaining was performed on the DAKO Autostai-
ner Plus. Positive and negative controls were stained
concurrently and showed appropriate immunostaining.
The extent of immunohistochemical staining was eval-
uated microscopically. Labeling for CK7 and AMACR
was considered positive when moderate to strong stain-
ing was present in greater than 20% of tumor cells.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) analysis was
performed as described previously [5,7,34-37]. Briefly,
multiple 4 μm sections were obtained from formalin-
fixed paraffin-embedded tissue blocks containing neo-
plastic tissue. A hematoxylin and eosin-stained slide
from each block was examined to identify areas of neo-
plastic tissue for FISH analysis. The slides were deparaf-
finized with 2 washes of xylene, 15 minutes each, and
subsequently washed twice with absolute ethanol, 10 mi-
nutes each, and then air-dried in a fume hood. Next, the
slides were treated with 0.1 mM citric acid (pH 6.0)
(Zymed, South San Francisco, CA) at 95°C for 10 mi-
nutes, rinsed in distilled water for 3 minutes, followed
by a wash of 2x standard saline citrate for 5 minutes. Di-
gestion was performed by applying 0.4 mL of pepsin
(5 mg/mL in 0.1 N HCl/0.9 NaCl) (Sigma, St Louis,
MO) at 37°C for 40 minutes. The slides were rinsed with
distilled water for 3 minutes, washed with 2x standard
saline citrate for 5 minutes and air-dried. The chromo-
somal probe directed against 3p25 (RP11-572 M14) was
obtained from Empire Genomics (Empire Genomics,
Buffalo, New York). Chromosome enumeration probes
(CEP) for chromosomes 3, 7, and 17 were obtained from
Vysis (Abbott, Downers Grove, IL).
Deletion of chromosome 3p was assessed using a
probe cocktail containing BAC clone probe to chromo-
some 3p25 (RP11-572 M14, Green) and CEP3 (Orange).
Chromosome 7 and 17 alterations were assessed using a
probe cocktail containing probe CEP7 (Green) and
CEP17 (Orange). The 3p25/CEP3 probe set and the
CEP7/CEP17 probe set were diluted with tDenHyb2
(Insitus, Albuquerque, NM) in ratios of 1:50 and 1:100,
respectively.
Analysis was performed in a manner similar to that
previously described [5,7,34-37]. In brief, for each slide
100 to 150 nuclei from tumor tissue were scored for
probe signals under the fluorescence microscope with
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deletion was based on previous studies of chromosome
deletions at 1p and 19q in oligodendrogliomas [38,39].
The cutoff value for 3p deletion was defined as a 3p25/
CEP3 ratio of ≤0.7. Definitions of chromosomal trisomy
for chromosomes 7 and 17 were based on the Gaussian
model and were related to the nonneoplastic renal cor-
tex control cell signals. The cutoff values were set for
each probe at the mean plus 3 standard deviations of the
control values. Chromosome 3p deletion was considered
to be characteristic of CCRCC, whereas trisomy of chro-




A total of 103 metastatic RCC specimens were included
in the study. Of these, 32 tumors were originally classi-
fied as metastatic CCRCC, and 8 were originally classi-
fied as metastatic PRCC, based on a constellation of
typical morphologic features and known histologic clas-
sification of the primary tumor. In the remaining 63
cases of metastatic RCC, the tumor histologic subtype
was unknown or uncertain, based on lack of availability
of tissue material from the primary tumor for compari-
son (including primary tumors that were not resected or
those diagnosed an another institution) and equivocal
morphologic features in the metastatic lesion. Seventy-
five patients were male and 28 were female. The pa-
tients’ ages ranged from 28 to 87 years (median 63 years).
The metastatic sites included: bone (n = 27), lung (n =
19), abdominal sites (n = 17), liver (n = 7), pleura (n = 7),
soft tissue (n = 7), pancreas (n = 3), gastrointestinal tract
(n = 3), mediastinum (n = 3), gallbladder (n = 2), thyroid
(n = 2), and other organs or tissues (n = 6).
Immunohistochemistry
Overall, 7% (7/103) of all metastatic RCC showed posi-
tive immunohistochemical staining for CK7, and 57%
(59/103) showed immunoreactivity for AMACR (Table 1,
Figures 1 and 2). Of the tumors originally classified as
metastatic CCRCC, none were positive for CK7 and 34%Table 1 Summary of IHC markers and cytogenetic abnormalit
mRCC Subtypes (n) IHC
CK7 AMACR
CCRCC (32) 0% (0/32) 34% (11/3
PRCC (8) 38% (3/8) 100% (8/
Not classified (63) 6% (4/63) 63% (40/6
Total (103) 7% (7/103) 57% (59/1
Abbreviations: mRCC, metastatic renal cell carcinoma; CCRCC, clear cell renal cell car
AMACR, alpha-methylacyl-CoA racemase.(11/32) were positive for AMACR. Of the tumors origin-
ally classified as metastatic PRCC, 38% (3/8) were posi-
tive for CK7, and 100% (8/8) were positive for AMACR.
Of the RCCs with an uncertain or unknown histologic
subtype, 6% (4/63) were positive for CK7, and 64% (40/
63) were positive for AMACR (Table 1). Of the CK7-
positive tumors, 86% (6/7) also demonstrated trisomy of
chromosomes 7 and/or 17 by FISH.
Cytogenetics
Chromosome 3p deletion was detected in 41% (42/103)
of all metastatic RCC cases, and trisomy of chromosomes
7 and/or 17 was detected in 16% (16/103), of which 14
exhibited trisomy of chromosome 7 and 12 exhibited
trisomy of chromosome 17 (Table 1). Of the tumors
originally classified as metastatic CCRCC, chromosome
3p deletion was detected in 63% (20/32). Of the tumors
originally classified as metastatic PRCC, 75% (6/8)
showed trisomy of chromosome 7 and/or 17. Deletions
of chromosome 3p and trisomy of chromosomes 7 and/
or 17 were mutually exclusive findings in these metastatic
CCRCC and PRCC cases. Of the RCCs not previously clas-
sified, 35% (22/63) were found to have chromosome 3p de-
letion, and 16% (10/63) were found to have trisomy of
chromosome 7 and/or 17 (Table 1). Therefore 51% (32/63)
of the metastatic RCCs that were previously not classified
could be subtyped based on cytogenetic alterations: The
tumors with chromosome 3p deletion (35%, 22/63) were
reclassified as metastatic CCRCC, and the tumors with tri-
somy 7 and/or 17 (16%, 10/63) were reclassified as meta-
static PRCC (Table 1, Figure 3).
Of the 22 tumors reclassified based on FISH results as
metastatic CCRCC, none were positive for CK7, and
46% (10/22) were positive for AMACR. Of the 10 cases
reclassified as metastatic PRCC, 30% (3/10) were positive
for CK7, and 100% (10/10) were positive for AMACR.
One tumor was positive for CK7 but lacked any cytogen-
etic abnormality detected by these methods. If this
tumor is regarded as PRCC based on positivity for CK7,
then 52% (33/63) of the metastatic RCCs that were not
previously subtyped could be reclassified based on a
combination of FISH and immunohistochemistry.ies in different metastatic RCC subtypes
Cytogenetics
3p deletion Trisomy 7 and/or 17
2) 63%(20/32) 0% (0/32)
8) 0% (0/8) 75% (6/8)
3) 35% (22/63) 16% (10/63)
03) 41% (42/103) 16% (16/103)
cinoma; PRCC, papillary renal cell carcinoma; IHC, immunohistochemistry;
Figure 1 Metastatic clear cell renal cell carcinoma. A metastatic tumor nodule in the lung (A) was composed of solid, nested, and tubular
arrangements of cells with clear cytoplasm (B). The tumor cells showed negative immunoreactivity for CK7 (C) but strong reactivity for AMACR
(D). Dual-color fluorescence in situ hybridization demonstrated chromosome 3p deletion, as indicated by the presence of a single 3p25 signal
(green) with two chromosome 3 centromere signals (red) per cell (E). Tumor nuclei showed two green signals for chromosome 7 and two red
signals for chromosome 17 (F), disomic patterns.
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RCC is known for its ability to metastasize either syn-
chronously or metachronously to a variety of anatomic
sites. In current practice, distinguishing histologic subtypesof metastatic RCC has become increasingly important, as
different subtypes portend divergent prognoses and are
managed with disparate treatment algorithms. Histologic
features enable accurate classification of most primary
Figure 2 Metastatic papillary renal cell carcinoma. A metastatic tumor nodule in the liver exhibited characteristic papillary architecture (A),
composed of fibrovascular cores lined by cells with eosinophilic cytoplasm (B). The tumor cells labeled strongly with antibodies to CK7 (C) and
AMACR (D). Dual-color fluorescence in situ hybridization revealed intact chromosome 3p, as indicated by two green signals (3p25) and two
chromosome 3 centromeric red signals (CEP3) (E). Dual-color fluorescence in situ hybridization demonstrated trisomy of chromosomes 7 and 17,
as evident by three green signals (CEP7) and three red signals (CEP17) in each tumor cell nucleus (F), supporting the classification of papillary
renal cell carcinoma.
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tween some categories of renal neoplasms can make sub-
classification difficult, particularly in the metastatic setting,in which biopsy material may be limited and high-grade
morphology may obscure prototypical histopathologic
architectural and cytologic features. Additionally, recent
Figure 3 Metastatic renal cell carcinomas not previously classified. A metastatic tumor nodule involving a lymph node (A) exhibited a
nested to sheet-like architecture (B). Although morphologic features supported a diagnosis of metastatic renal cell carcinoma, the precise
tumor subtype was not initially apparent. The tumor cells did not label for CK7 (C), but demonstrated moderately strong granular cytoplasmic
reactivity for AMACR (D). Dual-color fluorescence in situ hybridization revealed intact chromosome 3p (E) as indicated by two green signals
(3p25) and two red chromosome 3 centromeric signals (CEP3). FISH demonstrated trisomy of chromosomes 7 and 17, as indicated by three green
signals (CEP7) and three red signals (CEP17) per nucleus (F), supporting reclassification of this tumor as papillary renal cell carcinoma. Another
metastatic renal cell carcinoma involving the lung showed architectural and cytologic features not initially recognizable as those of a particular
renal cell carcinoma subtype (G). The tumor exhibited a mixture of solid, trabecular, and tubulopapillary growth, lined by cells with eosinophilic
cytoplasm (H). Dual-color fluorescence in situ hybridization demonstrated a characteristic 3p25 deletion as indicated by one green signal (3p25)
and two chromosome 3 centromere red signals (CEP3) per cell (I), supporting subtyping as high-grade manifestation of clear cell renal cell carcin-
oma. A third metastatic lesion involving bone (J) contained cells with clear cytoplasm and prominent nucleoli, dispersed in a hemorrhagic and fi-
brinous (K) background. These morphologic findings raised the possibility of metastatic clear cell renal cell carcinoma. However, FISH revealed
trisomy of chromosomes 7 and 17 (L), as demonstrated by three green signals (CEP7) and three red signals (CEP17) per nucleus. These findings
were in line with the patient’s history of papillary renal cell carcinoma resected via radical nephrectomy many years prior, despite the morpho-
logic appearance raising the possibility of clear cell renal cell carcinoma.
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RCC have revealed substantial heterogeneity in genetic
alterations in different regions of metastatic deposits
and within different regions of the primary tumor [40].
In the era of targeted therapies, different histologic
subtypes of metastatic RCC have relevance in selecting
patients for enrollment in clinical trials and in evalu-
ation for salvage therapy [1,8,41]. Currently, pivotal
studies using targeted drugs have largely focused on pa-
tients with clear cell RCC. Patients with tumors of
other non-clear cell histologic subtypes have been less
extensively studied [27]. In the present study, we evalu-
ated the immunophenotypes of 103 metastatic RCCs,
and correlated with the tumors’ cytogenetic character-
istics using FISH. Combined analysis of immunohisto-
chemistry and cytogenetics enabled reclassification of
52% (33/63) of metastatic RCCs for which the histo-
logic subtype was originally unknown or uncertain.
Our study establishes the utility of immunohistochem-
istry and cytogenetics for subtyping metastatic RCC,
which may be of particular help toward selecting ap-
propriate targeted therapies.
RCC is not a single disease; it is composed of a num-
ber of subtypes, each with unique histologic features,
genetic alterations, clinical behavior, and response to
therapy [1,7,8,42]. Nonetheless, histologic subtyping of
RCC can be particularly problematic in the metastatic
setting for a number of reasons: For one, tissue diagnosis
of metastatic RCC is sometimes established prior to
or in the absence of sampling the primary tumor.
Conversely, identification of metastatic RCC sometimes
follows resection of the primary tumor by a long in-
tervening period. Further, metastatic RCC may prefer-
entially exhibit high-grade morphology, lacking the
characteristic cytologic and architectural features that
are often admixed with higher-grade components in
the primary tumor. Therefore, some metastatic RCCs
present as a tumor of unknown origin, with a prior his-
tory of RCC unknown to treating oncologists or pathol-
ogists. In the metastatic context, core needle biopsies
and fine needle aspiration specimens from metastatic
RCC may be particularly challenging due to limited
material for evaluation [43].
Advances in biologic and genetic understanding of
RCC have led to specifically targeted treatments for
metastatic RCC. For example, inhibition of targets in the
HIF pathway has resulted in significant clinical re-
sponses in CCRCC [44,45]. Loss of activity of the Krebs
cycle enzyme fumarase hydratase (FH) in some cases of
papillary type II RCC may also result in HIF upregula-
tion [46], potentially providing an avenue for utilization
of similar treatments in patients with PRCC. Activation
of the c-MET oncogene is characteristic of papillary
RCC type I, particularly in the hereditary PRCCsyndrome and a subset of sporadic PRCC [8]. This find-
ing offers a clear opportunity to test newly developed in-
hibitors of this tyrosine kinase in this subset of RCC
[44,47]. Although these effective biologic agents may be
used in a more individualized approach to metastatic
RCC therapy, their novelty infers a paucity of clinical
data about their toxic effects or management of their
therapy-limiting complications in the setting of meta-
static RCC [30]. Therefore, histological subtyping of
metastatic RCC significantly impact clinical decision
making and therapeutic outcomes in these patients.
CK7 and AMACR have been proposed as markers to
help distinguish PRCC from other RCC types, especially
CCRCC [34,36,48-51]. Immunostaining for CK7 in
CCRCC is usually negative or only focally positive, con-
trasting with more diffuse labeling for this protein in
many PRCCs [50-53], particularly type I PRCC. Diffuse,
strong AMACR expression is typical of PRCC (70-
100%); however, reactivity has also been observed to a
variable extent in 4-68% of CCRCC [49,50,54-58], some-
times less diffusely or associated with higher-grade
tumor components. When evaluating these two markers
for RCC, focus has been predominantly directed at pri-
mary tumors. We performed immunohistochemical
staining for CK7 and AMACR in this series of 103 non-
primary cases to confirm their expression in metastatic
RCC. None of the metastatic CCRCC met the study
threshold for positive CK7 staining. Only 38% (3/8) of
the metastatic PRCC and 6% (4/63) of the RCCs that
were previously not classified were positive for CK7,
suggesting that expression of this marker may be attenu-
ated in metastatic RCC. CK7 was relatively specific for
metastatic PRCC, although not as sensitive as AMACR,
perhaps due to its expression in predominantly type I ra-
ther than type II tumors [59]. AMACR was detected in
23 of 28 metastatic CCRCC (82%) in one study [60], and
6 of 6 metastatic PRCC (100%) in another study [61]. In
our study, AMACR was expressed by 57% (59/103) of
all metastatic RCC, including 11 cases of metastatic
CCRCC (34%, 11/32), all metastatic PRCCs (100%, 8/8),
and 40 cases of RCC not previously classified (63%, 40/
63). AMACR was relatively sensitive for metastatic
PRCC, but its specificity was not high. Therefore, the
value of CK7 and AMACR immunostaining alone is
limited for accurately subtyping metastatic RCC.
Other immunohistochemical antibodies with emerging
utility in the subclassification of RCC include those di-
rected against carbonic anhydrase IX [62-64]. Since this
enzyme is a downstream target of the VHL-HIF pathway
[64-66], it is reported to exhibit diffuse, strong mem-
branous reactivity by immunohistochemistry in CCRCC,
in contrast to other subtypes of renal tumors, which typ-
ically exhibit focal or multifocal reactivity [63], some-
times juxtaposed to areas of ischemia or necrosis.
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heterogeneity using this marker, particularly in high-
grade or sarcomatoid tumors, such as those that might
be encountered at a metastatic site [67]. Since tissue
sampling of a metastatic tumor is also likely to be lim-
ited, the significance of positive reactivity for carbonic
anhydrase IX may be uncertain compared to large sam-
ples from a completely resected tumor, in which extent
of reactivity can be more readily assessed.
Interphase cytogenetic analysis has emerged as a
powerful tool for diagnosis and classification of RCC
[34,68-72]. The cytogenetic hallmark of CCRCC is loss
of chromosome 3p, the chromosomal site of the VHL
gene and other important loci involved in CCRCC
tumorigenesis [8,33]. FISH analysis shows the character-
istic chromosome 3p deletion in 60-90% of CCRCC
cases [33,73]. In contrast, PRCC frequently exhibits
chromosomal polysomies, of which trisomy of chromo-
somes 7 and/or 17 are the most consistent and charac-
teristic [34]. The current study provides cytogenetic data
for metastatic RCC involving a variety of anatomic sites.
Chromosome 3p deletion was detected in 41% (42/103)
of all metastatic RCC cases, and in 63% (20/32) of
tumors originally diagnosed as metastatic CCRCC. Of
tumors originally diagnosed as metastatic PRCC, 75%
(6/8) showed trisomy of chromosomes 7 or 17. Of the
metastatic RCCs that were not originally classified, 35%
(22/63) additionally exhibited chromosome 3p deletion,
facilitating reclassification as metastatic CCRCC. An
additional 16% of these tumors (10/63) were found to
have trisomy of chromosomes 7 and/or 17, supporting
reclassification as metastatic PRCC. In this study, we
found chromosome 3p deletion and trisomy 7 or 17 to
be mutually exclusive in metastatic RCCs; however,
other investigators have occasionally found chromosome
3p deletion to coexist with trisomy 7 or 17 in PRCC,
such as in some type II PRCC, and some CCRCC
[8,69,72,74]. Therefore, when both of these alterations
are present in the same tumor, the findings should be
interpreted with caution in supporting the diagnosis of a
particular RCC subtype. One additional tumor was
found to have no cytogenetic abnormality by FISH but
positive expression of CK7 by immunohistochemistry. If
this tumor is also considered to be PRCC based on this
immunoreactivity pattern, 52% (33/63) of the metastatic
RCCs that were previously not classified could be sub-
typed based on the combination of immunohistochemis-
try and FISH. A limitation of this study is that we
assessed primarily only the two most common RCC sub-
types, CCRCC and PRCC. However, a number of other
RCC subtypes are now increasingly recognized [75],
such as those associated with translocations involving
MITF family genes [1,7,8,76-79]. Such neoplasms often
exhibit overlapping morphologic features of CCRCC andPRCC, yet they are characterized by unique clinicopath-
ologic, immunohistochemical and genetic alterations. In
contrast to the 3p deletions and trisomy of chromo-
somes 7 and 17 in CCRCC and PRCC, respectively,
FISH analysis has assumed a key role in confirming rear-
rangements involving the TFE3 gene in such tumors
[1,78,79] and to a lesser extent, the TFEB gene [80].
In summary, subtyping of metastatic RCC has become
increasingly important with the emergence of novel ther-
apies for specific tumor subtypes. Our data support the
utility of a combined approach of immunohistochemistry
and cytogenetics for subtyping metastatic RCC. Our
findings may have important diagnostic and clinical im-
plications in the era of personalized medicine, with the
advent of target-specific therapeutics.
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